2. Gene
  3. Vhl - von Hippel-Lindau tumor suppressor Gene

Vhl - von Hippel-Lindau tumor suppressor Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

种属: Mus musculus

同用名: Vhlh; pVHL

基因 ID: 22346 | 基因类型: protein coding

关于 Vhl

功能概要

Predicted to enable enzyme binding activity and ubiquitin ligase-substrate adaptor activity. Involved in regulation of postsynapse organization and regulation of protein catabolic process at postsynapse, modulating synaptic transmission. Acts upstream of or within several processes, including camera-type eye morphogenesis; enteroendocrine cell differentiation; and regulation of apoptotic process. Located in several cellular components, including cilium; glutamatergic synapse; and nuclear lumen. Part of Cul2-RING ubiquitin Ligase complex. Is expressed in several structures, including eye; genitourinary system; gut; heart; and nervous system. Used to study familial erythrocytosis 2; sudden infant death syndrome; and von Hippel-Lindau disease. Human ortholog(s) of this gene implicated in several diseases, including pancreatic Cancer (multiple); pheochromocytoma; polycythemia (multiple); renal cell carcinoma; and von Hippel-Lindau disease. Orthologous to several human genes including VHL (von Hippel-Lindau tumor suppressor). [provided by Alliance of Genome Resources, Apr 2022]

Vhl 基因产物(1)

mRNA Protein Name
NM_009507.4 NP_033533.1 von Hippel-Lindau disease tumor suppressor
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables protein binding IPI
IPI: 通过物理相互作用推断
15601820 MGI
enables protein-containing complex binding IDA
IDA: 通过直接分析推断
17825299 MGI
生物过程 GO 注释 逻辑证据 参考文献 来源
acts upstream of or within angiogenesis IMP
IMP: 通过突变表型推断
16537898 MGI
acts upstream of or within blood vessel endothelial cell migration IMP
IMP: 通过突变表型推断
16537898 MGI
acts upstream of or within camera-type eye morphogenesis IGI
IGI: 通过遗传相互作用推断
22627278 MGI
acts upstream of or within camera-type eye morphogenesis IMP
IMP: 通过突变表型推断
22627278 MGI
acts upstream of or within ciliary body morphogenesis IMP
IMP: 通过突变表型推断
22627278 MGI
acts upstream of endothelial cell differentiation IMP
IMP: 通过突变表型推断
25186293 MGI
acts upstream of or within extracellular matrix organization IMP
IMP: 通过突变表型推断
16537898 MGI
acts upstream of or within eye pigmentation IMP
IMP: 通过突变表型推断
22627278 MGI
acts upstream of or within homeostasis of number of retina cells IMP
IMP: 通过突变表型推断
22627278 MGI
acts upstream of hypoxia-inducible factor-1alpha signaling pathway IMP
IMP: 通过突变表型推断
25186293 MGI
acts upstream of or within iris morphogenesis IGI
IGI: 通过遗传相互作用推断
22627278 MGI
acts upstream of or within iris morphogenesis IMP
IMP: 通过突变表型推断
22627278 MGI
acts upstream of or within melanin metabolic process IMP
IMP: 通过突变表型推断
22627278 MGI
acts upstream of or within negative regulation of endothelial cell differentiation IMP
IMP: 通过突变表型推断
25186293 MGI
acts upstream of or within negative regulation of gene expression IMP
IMP: 通过突变表型推断
22627278 MGI
acts upstream of or within negative regulation of hypoxia-inducible factor-1alpha signaling pathway IMP
IMP: 通过突变表型推断
25186293 MGI
acts upstream of or within negative regulation of thymocyte apoptotic process IMP
IMP: 通过突变表型推断
15456877 MGI
acts upstream of or within pancreatic A cell differentiation IMP
IMP: 通过突变表型推断
25186293 MGI
acts upstream of or within positive regulation of epithelial cell proliferation IMP
IMP: 通过突变表型推断
22627278 MGI
acts upstream of or within proteasomal protein catabolic process IMP
IMP: 通过突变表型推断
17981124 MGI
acts upstream of or within protein catabolic process IMP
IMP: 通过突变表型推断
12832481 MGI
acts upstream of or within protein transport IDA
IDA: 通过直接分析推断
16129783 MGI
acts upstream of or within regulation of apoptotic signaling pathway IGI
IGI: 通过遗传相互作用推断
15456877 MGI
acts upstream of or within regulation of gene expression IMP
IMP: 通过突变表型推断
22627278 MGI
involved in regulation of postsynapse organization IDA
IDA: 通过直接分析推断
26972007 MGI
involved in regulation of postsynapse organization IEP
IEP: 通过表达模式推断
26972007 MGI
involved in regulation of postsynapse organization IMP
IMP: 通过突变表型推断
26972007 MGI
acts upstream of or within regulation of protein localization IMP
IMP: 通过突变表型推断
22627278 MGI
acts upstream of or within regulation of thymocyte apoptotic process IGI
IGI: 通过遗传相互作用推断
15456877 MGI
involved in regulation protein catabolic process at postsynapse IDA
IDA: 通过直接分析推断
26972007 MGI
involved in regulation protein catabolic process at postsynapse IEP
IEP: 通过表达模式推断
26972007 MGI
involved in regulation protein catabolic process at postsynapse IMP
IMP: 通过突变表型推断
26972007 MGI
acts upstream of or within type B pancreatic cell differentiation IMP
IMP: 通过突变表型推断
25186293 MGI
细胞组分 GO 注释 逻辑证据 参考文献 来源
part of Cul2-RING ubiquitin ligase complex IDA
IDA: 通过直接分析推断
16129783 MGI
located in cilium IDA
IDA: 通过直接分析推断
17825299 MGI
located in cytoplasm IDA
IDA: 通过直接分析推断
16129783 MGI
is active in glutamatergic synapse IDA
IDA: 通过直接分析推断
26972007 MGI
is active in glutamatergic synapse IEP
IEP: 通过表达模式推断
26972007 MGI
is active in glutamatergic synapse IMP
IMP: 通过突变表型推断
26972007 MGI
located in nucleolus IDA
IDA: 通过直接分析推断
16129783 MGI
located in nucleoplasm IDA
IDA: 通过直接分析推断
16129783 MGI
located in nucleus IDA
IDA: 通过直接分析推断
16129783 MGI
is active in postsynaptic density IDA
IDA: 通过直接分析推断
26972007 MGI
is active in postsynaptic density IEP
IEP: 通过表达模式推断
26972007 MGI
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断
蛋白主名 其他名称

von Hippel-Lindau disease tumor suppressor

von Hippel-Lindau syndrome protein homolog

相关产品

Approval
生物活性分子 (2)
目录号 产品名 作用方式
纯度 是否罕见病
HY-13001 Quizartinib 99.08% 是
HY-14217 Quizartinib dihydrochloride 99.81% 否
Clinical Phase
生物活性分子 (4)
目录号 产品名 作用方式
纯度 Phase
HY-156730 KT-333 Degrader 96.17% Phase 1
HY-162362 MS8709 Degrader 99.87% Phase 1
HY-156730A KT-333 ammonium Degrader 99.48% Phase 1
HY-156730B KT-333 diammonium Degrader / Phase 1
Pre-clinical Phase
生物活性分子 (342)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-145514 dTAGV-1 TFA Degrader 99.97% 否
HY-130604 DT2216 99.97% 否
HY-100947 VH-298 Inhibitor 99.78% 否
HY-120217 VH032 99.64% 否
HY-111997 VH285-PEG4-C4-Cl ≥98.0% 否
HY-111431 p-Cresyl sulfate 99.87% 否
HY-42424 (S,R,S)-AHPC-Me hydrochloride 99.95% 否
HY-137516 LC-2 Inhibitor 98.16% 否
HY-153321 Bexobrutideg Degrader 99.33% 否
HY-125845 (S,R,S)-AHPC 99.13% 否
HY-151623 ACBI2 Inhibitor 99.76% 否
HY-18728 STF-31 99.79% 否
HY-101763A (S,R,S)-AHPC monohydrochloride 99.83% 否
HY-132296 GSK215 Inhibitor 99.26% 否
HY-130492 ARCC-4 Inhibitor 99.88% 否
HY-113491 3-Phosphoglyceric acid Chemical 99.88% 否
HY-112078 (S,R,S)-AHPC-Me 99.96% 否
HY-148030 XL01126 Inhibitor 98.90% 否
HY-145479 PROTAC AR-V7 degrader-1 Inhibitor 98.19% 否
HY-160415A WD6305 TFA 99.81% 否
HY-129937A GNE-987 Inhibitor 99.73% 否
HY-153863 MS934 Degrader 98.48% 否
HY-103598 (S,R,S)-AHPC-PEG3-N3 99.67% 否
HY-145514C dTAGV-1 hydrochloride Degrader 98.83% 否
HY-119932 PROTAC FAK degrader 1 Inhibitor 99.25% 否
HY-128600 ERD-308 Inhibitor 99.05% 否
HY-152154 Nampt degrader-2 99.41% 否
HY-153188 JNJ-1013 99.80% 否
HY-145816A JPS016 TFA 99.47% 否
HY-103601 (S,R,S)-AHPC-PEG4-N3 99.93% 否
HY-103602 (S,R,S)-AHPC-PEG3-NH2 hydrochloride 99.01% 否
HY-136262 CRBN-6-5-5-VHL Degrader 99.45% 否
HY-141438 SIM1 Inhibitor 99.57% 否
HY-130271 (S,R,S)-AHPC-PEG5-COOH 99.80% 否
HY-125834 GMB-475 98.69% 否
HY-125878 PROTAC SGK3 degrader-1 Inhibitor 99.89% 否
HY-130257 CP5V Inhibitor 99.31% 否
HY-130602 MS432 Inhibitor 99.72% 否
HY-145162 SHP2-D26 Inhibitor 95.83% 否
HY-44432 Navitoclax-piperazine Inhibitor 99.73% 否
HY-112495 VH032-PEG5-C6-Cl 99.93% 否
HY-103604A (S,R,S)-AHPC-PEG4-NH2 99.51% 否
HY-103599 (S,R,S)-AHPC-PEG2-N3 99.94% 否
HY-125845A (S,S,S)-AHPC hydrochloride 99.16% 否
HY-125905 VH032-cyclopropane-F 99.92% 否
HY-130815A MAK683-CH2CH2COOH hydrochloride Inhibitor 98.03% 否
HY-132857A ZXH-4-130 TFA 99.71% 否
HY-139218 (S,R,S)-AHPC-Me-C6-NH2 99.81% 否
HY-156106 VHL-IN-1 99.84% 否
HY-128756 SIAIS178 Inhibitor 99.36% 否
HY-103600 (S,R,S)-AHPC-PEG1-N3 98.18% 否
HY-103603 (S,R,S)-AHPC-PEG2-NH2 hydrochloride 99.77% 否
HY-163897 PROTAC NCOA4 degrader-1 Inhibitor 99.42% 否
HY-47070 VH 101, acid 98.82% 否
HY-128845 PROTAC CRBN Degrader-1 Degrader 99.84% 否
HY-136001 PROTAC α-synuclein degrader 3 Degrader 99.61% 否
HY-153119 TMX-4153 98.96% 否
HY-159788 PROTAC K-Ras Degrader-4 Degrader 99.01% 否
HY-128767 VH032-PEG3-acetylene 98.14% 否
HY-100746 STF-62247 Inducer 98.69% 否
HY-156568 SMD-3040 Degrader 99.91% 否
HY-156568B SMD-3040 formate Degrader 99.78% 否
HY-162608 PROTAC JAK1 degrader 1 Degrader 99.97% 否
HY-B2171A Carubicin hydrochloride Inducer 98.33% 否
HY-114402 ARD-69 Degrader 99.61% 否
HY-162250 MS8847 Inhibitor 99.78% 否
HY-130979 EED226-COOH 99.88% 否
HY-148896 (S,R,S)-AHPC-C2-PEG3-BCN 99.22% 否
HY-155815 MS9715 Inhibitor 97.60% 否
HY-130714 TD-165 Inhibitor 99.41% 否
HY-103605 (S,R,S)-AHPC-C6-PEG3-C4-Cl 97.01% 否
HY-126456 (S,R,S)-AHPC-propargyl 99.46% 否
HY-133045 VHL Ligand 8 98.04% 否
HY-137346 DD-03-156 Degrader 99.90% 否
HY-148671 (S,R,S)-AHPC-amido-C7-acid 98.71% 否
HY-111663 VL285 99.34% 否
HY-145815A JPS014 TFA 98.40% 否
HY-169093 MS41 97.14% 否
HY-131865 SJF-1521 Degrader 99.65% 否
HY-133737 PROTAC BRD4 Degrader-5 Inhibitor 99.87% 否
HY-168555 YJ1206 96.36% 否
HY-123109 (S,R,S)-AHPC-Boc 95.21% 否
HY-130798 (S,R,S)-AHPC-amido-C5-acid 99.58% 否
HY-103604 (S,R,S)-AHPC-PEG4-NH2 hydrochloride 98.06% 否
HY-123109A (S,S,S)-AHPC-Boc Control 97.21% 否
HY-150803 VHL Ligand 14 99.93% 否
HY-158142 PROTAC TYK2 degrader-1 Degrader 99.55% 否
HY-171140 PROTAC HDAC6 degrader 3 Degrader 99.81% 否
HY-42424A (S,R,S)-AHPC-Me dihydrochloride 99.84% 否
HY-111905 BRD7-IN-1 Inhibitor 99.77% 否
HY-114323 PROTAC FLT-3 degrader 1 99.74% 否
HY-133487B (S,R,S)-AHPC-C8-NH2 97.04% 否
HY-122702 PEG6-(CH2CO2H)2 ≥95.0% 否
HY-130716 Thalidomide-NH-C10-COOH Inducer 97.50% 否
HY-130845A AR antagonist 1 hydrochloride Antagonist 99.53% 否
HY-131388 ABM-14 98.17% 否
HY-138678 (R,S,S)-VH032 98.99% 否
HY-143275 HL-8 Inhibitor 99.17% 否
HY-156152A CARM1 degrader-1 hydrochloride Degrader 99.44% 否
HY-164995 L1BC8 Inhibitor 99.20% 否
HY-135045 (S,R,S)-AHPC-C4-COOH 95.92% 否
HY-114176B (S,R,S)-AHPC-C4-NH2 dihydrochloride / 否
HY-130849 (S,R,S)-AHPC-Me-C5-COOH 96.87% 否
HY-136163 (S,R,S)-AHPC-C2-NH2 dihydrochloride 98.63% 否
HY-136183 (S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride 98.16% 否
HY-136184 (S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride 99.01% 否
HY-103608 (S,R,S)-AHPC-(C3-​PEG)​2-​C6-​Cl 99.89% 否
HY-130711B (S,R,S)-AHPC-C3-NH2 hydrochloride 96.38% 否
HY-131295 PD0325901-O-C2-dioxolane Inhibitor 98.62% 否
HY-136006B (S,R,S)-AHPC-C6-NH2 98.03% 否
HY-158345 PROTAC VHL-type degrader-1 98.01% 否
HY-47851 VH 101, thiol 98.66% 否
HY-145264 OARV-771 Inhibitor 98.33% 否
HY-159147 SIA​​IS039 99.68% 否
HY-130991 K-Ras ligand-Linker Conjugate 6 / 否
HY-131387 (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 96.12% 否
HY-103606 (S,R,S)-AHPC-PEG6-C4-Cl 96.24% 否
HY-103607 (S,R,S)-AHPC-PEG2-C4-Cl 98.21% 否
HY-131866 (S,R,S)-CO-C2-acid ≥98.0% 否
HY-136257 CMP98 99.72% 否
HY-138550A (S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 TFA 99.42% 否
HY-148065 FMF-06-098-1 Inhibitor 98.77% 否
HY-153598 LD4172 Degrader / 否
HY-156568A SMD-3040 TFA Degrader 99.90% 否
HY-163167 VH 032 amide-alkylC5-azide 98.32% 否
HY-130815 MAK683-CH2CH2COOH Inhibitor / 否
HY-131959 (S,R,S)-AHPC-PEG5-Boc 95.29% 否
HY-133487A (S,R,S)-AHPC-C8-NH2 hydrochloride / 否
HY-136006A (S,R,S)-AHPC-C6-NH2 hydrochloride / 否
HY-103602A (S,R,S)-AHPC-PEG3-NH2 99.26% 否
HY-103603A (S,R,S)-AHPC-PEG2-NH2 95.41% 否
HY-103603B (S,R,S)-AHPC-PEG2-NH2 dihydrochloride ≥95.0% 否
HY-130642 (S,R,S)-AHPC-Me-C10-Br 98.02% 否
HY-130707 K-Ras ligand-Linker Conjugate 3 / 否
HY-130816 (S,R,S)-AHPC-O-Ph-PEG1-NH2 96.97% 否
HY-130823 K-Ras ligand-Linker Conjugate 5 99.79% 否
HY-136164 VH032-OH 99.43% 否
HY-136165 (S,R,S)-AHPC-PEG3-propionic acid 97.03% 否
HY-44148 FAK ligand-Linker Conjugate 1 98.91% 否
HY-111823 VH032 thiol 95.91% 否
HY-114176 (S,R,S)-AHPC-C4-NH2 hydrochloride ≥97.0% 否
HY-136005 VH032-C7-COOH 99.92% 否
HY-136008 (S,R,S)-AHPC-PEG1-NH2 98.48% 否
HY-136187A (S,R,S)-AHPC-C5-NH2 dihydrochloride 97.8% 否
HY-138861A (S,R,S)-AHPC-C1-NH2 hydrochloride 98.08% 否
HY-138862 (S,R,S)-AHPC-C1-Br ≥98.0% 否
HY-141797 MS33 Inhibitor / 否
HY-151227 VL285 Phenol 98.56% 否
HY-158684 YX-02-030 Degrader 99.86% 否
HY-159798 NR-11c Inhibitor 99.75% 否
HY-162553 GNE7599 / 否
HY-131890 VH032 amide-PEG1-acid 97.12% 否
HY-173011 RJS308 / 否
HY-129775 K-Ras ligand-Linker Conjugate 1 / 否
HY-129776 K-Ras ligand-Linker Conjugate 2 / 否
HY-129941 (S,R,S)-AHPC-C10-NH2 / 否
HY-13001S Quizartinib-d8 / 否
HY-130711A (S,R,S)-AHPC-C3-NH2 TFA / 否
HY-133487 (S,R,S)-AHPC-C8-NH2 dihydrochloride / 否
HY-136006 (S,R,S)-AHPC-C6-NH2 dihydrochloride / 否
HY-136055 (S,R,S)-AHPC-C5-COOH Inhibitor 98.81% 否
HY-141486 (Rac)-PROTAC PARP/EGFR ligand 1 / 否
HY-156744 DBr-1 Degrader 98.87% 否
HY-159607 PRT3789 Degrader / 否
HY-173422 MS2133 Degrader / 否
HY-114176A (S,R,S)-AHPC-C4-NH2 / 否
HY-125846 (S,R,S)-AHPC-PEG1-OTs / 否
HY-125906 VHL Ligand-Linker Conjugates 15 / 否
HY-129941A (S,R,S)-AHPC-C10-NH2 dihydrochloride 96.74% 否
HY-130711 (S,R,S)-AHPC-C3-NH2 / 否
HY-130822 K-Ras ligand-Linker Conjugate 4 98.76% 否
HY-130847 (S,R,S)-AHPC-Me-C10-NH2 96.19% 否
HY-136008A (S,R,S)-AHPC-PEG1-NH2 dihydrochloride / 否
HY-100947A cis VH-298 / 否
HY-101763B (S,R,S)-AHPC dihydrochloride / 否
HY-103602B (S,R,S)-AHPC-PEG3-NH2 dihydrochloride / 否
HY-112078A (S,R,S,R)-AHPC-Me / 否
HY-114322A cis-VZ185 Degrader / 否
HY-130641 Br-C10-methyl ester 97.87% 否
HY-130654 (S,R,S)-AHPC-C2-PEG4-N3 / 否
HY-130711C (S,R,S)-AHPC-C3-NH2 dihydrochloride / 否
HY-131168 (S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH 99.31% 否
HY-132857 ZXH-4-130 / 否
HY-133046 VHL Ligand-Linker Conjugates 17 / 否
HY-136163A (S,R,S)-AHPC-C2-NH2 / 否
HY-136186 (S,R,S)-AHPC-C7-amine / 否
HY-136186B (S,R,S)-AHPC-C7-amine hydrochloride / 否
HY-136187 (S,R,S)-AHPC-C5-NH2 / 否
HY-137516A LC-2 epimer / 否
HY-138678B (S,R,R)-VH032 / 否
HY-138861 (S,R,S)-AHPC-C1-NH2 / 否
HY-139335 VH 101 phenol-alkylC4-amine dihydrochloride / 否
HY-141651 (S,R,S)-AHPC-C3-COOH / 否
HY-144323 YF135 Inhibitor / 否
HY-145514B dTAGV-1-NEG TFA / 否
HY-145715 Azido-PEG2-VHL / 否
HY-145815 JPS014 / 否
HY-145816 JPS016 / 否
HY-145818 JPS035 / 否
HY-145819 JPS036 / 否
HY-146022 SIAIS117 Inhibitor / 否
HY-147174 PROTAC_ERRα Inhibitor 99.71% 否
HY-147235 RIPK2-IN-2 Inhibitor / 否
HY-147373 DA-PROTAC / 否
HY-148406 (S,R,S)-AHPC-C10-NHBoc 98.32% 否
HY-155356 YN14 Degrader / 否
HY-155506 NAMPT degrader-3 Degrader / 否
HY-155643 PROTAC TG2 degrader-1 Inhibitor / 否
HY-156152 CARM1 degrader-1 Inhibitor / 否
HY-156153 CARM1 degrader-2 Inhibitor / 否
HY-157512 SJF-0661 / 否
HY-157590 E3 ligase Ligand-Linker Conjugate 32 / 否
HY-157593 E3 ligase Ligand-Linker Conjugate 35 / 否
HY-157596 E3 ligase Ligand-Linker Conjugate 40 / 否
HY-157597 E3 ligase Ligand-Linker Conjugate 42 / 否
HY-157598 E3 ligase Ligand-Linker Conjugate 46 / 否
HY-157634 E3 Ligase Ligand-linker Conjugate 91 / 否
HY-157752 E3 Ligase Ligand-linker Conjugate 101 / 否
HY-157753 E3 Ligase Ligand-linker Conjugate 102 / 否
HY-157754 E3 Ligase Ligand-linker Conjugate 103 / 否
HY-158036 PROTAC STING Degrader-2 Degrader / 否
HY-158046 UNC8899 Degrader / 否
HY-158047 UNC8900 Degrader / 否
HY-158048 UNC9036 Degrader / 否
HY-158429 PROTAC CYP1B1 degrader-2 Degrader / 否
HY-158685 RG7112D MDM2 Inhibitor / 否
HY-159175 XM-U-14 / 否
HY-159457 PROTAC SMARCA2/4-degrader-6 Degrader / 否
HY-160415 WD6305 / 否
HY-160555 (S,R,S)-AHPC-CO-C9-NH2 / 否
HY-160555A (S,R,S)-AHPC-CO-C9-NH2 hydrochloride 98.79% 否
HY-160924 MS147 Inhibitor / 否
HY-161132 Lenalidomide 4'-alkyl-C5-azide / 否
HY-161194 (S,R,S)-AHPC-acetyl-azetidine-PIP-boc / 否
HY-161207 (S,R,S)-AHPC-acetyl-Pip-O-azetidine-boc / 否
HY-161367 VHL-SF2 / 否
HY-161368 BRD-SF2 Degrader / 否
HY-161445 (S,R,S)-AHPC-Me-piperazine-acetyl-PIP-AcOH / 否
HY-162193 E3 Ligase Ligand-linker Conjugate 27 / 否
HY-162202 E3 Ligase Ligand-linker Conjugate 50 / 否
HY-162450 Antitumor agent-150 / 否
HY-162538 LC-MI-3 / 否
HY-162834 PROTAC SMARCA2/4-degrader-27 Degrader / 否
HY-162835 PROTAC SMARCA2/4-degrader-28 Degrader / 否
HY-162930 PROTAC METTL3 degrader 1 Degrader / 否
HY-162943 P60-L3-VHL / 否
HY-162947 2-(2-(2-(6-Azidohexanamido)ethoxy)ethoxy)acetic acid / 否
HY-163209 VH 032 amide-PEG6-amine hydrochloride / 否
HY-163215 (S)-PROTAC PTK6 ligand-O-4,4-dimethylpiperidine-Boc / 否
HY-163216 PROTAC PTK6 ligand-O-4,4-dimethylpiperidine-Boc / 否
HY-163217 PROTAC PTK6 ligand-2,7-diazaspiro[3.5]nonane-Boc / 否
HY-163219 VHL Ligand 8-PEG2-O-piperidine-Boc / 否
HY-163220 (S,R,S)-AHPC-CO-CH2-O-CH2-piperidine-Boc / 否
HY-163223 (S,R,S)-AHPC-CO-CH2-piperazine-C3-piperazine-Boc / 否
HY-163224 (S)-PROTAC PTK6 ligand-O-C2-O-piperidine-Boc / 否
HY-163228 PROTAC PTK6 ligand-O-C2-O-piperidine-Boc / 否
HY-163231 (S,R,S)-AHPC-CO-CH2-azetidine-piperazine-CH2-COOH / 否
HY-163440 PROTAC NAMPT Degrader-1 Degrader / 否
HY-163845 YX862 Degrader / 否
HY-163872 PROTAC SMARCA2/4-degrader-10 Degrader / 否
HY-164977 JCS-1 Inhibitor / 否
HY-168026 CEP1347-VHL-02 / 否
HY-168027 CEP-1347-acid / 否
HY-168234 PROTAC SMARCA2 degrader-31 Inhibitor / 否
HY-168451 trans-VH 101-Thiol-C-cyclohexane-p-C-OTs / 否
HY-168453 dBAZ2B Degrader / 否
HY-168454 trans-VH032-Cyclopropane-F-C-cyclohexane-p-C-OTs / 否
HY-168487 PROTAC WDR5 degrader 1 / 否
HY-168969 AA-BR-157 / 否
HY-169264 SJYHJ-026 / 否
HY-169395 (S,R,S)-AHPC-CO-PEG-C2-iodine / 否
HY-170343 PROTAC SMARCA2 degrader-32 Degrader / 否
HY-170352 E3 Ligase Ligand-linker Conjugate 150 / 否
HY-170390 AB3067 Degrader / 否
HY-170413 PROTAC BTK Degrader-12 Degrader / 否
HY-170620 PROTAC PARP1 degrader-4 Inhibitor / 否
HY-170769 FLT3 Ligand-Linker Conjugate 1 Inhibitor / 否
HY-170824 SMD-3236 Degrader / 否
HY-170995 PROTAC ROR1 degrader-1 / 否
HY-170996 ROR1 ligand-1 Degrader / 否
HY-171658 R1-ICR-5 / 否
HY-171830 MS105 / 否
HY-172625 VH 101-amide-piperidine-Pip-alkyne / 否
HY-172645 (S,R,S)-AHPC-Me-amide-C-O-C5-Br / 否
HY-172767 STAT3-D11-PROTAC-VHL / 否
HY-172948 VHL Ligand 36 / 否
HY-173010 Me-(S,R,S)-AHPC-CO-C5-N3 / 否
HY-173333 PROTAC SMARCA2/4 degrader-38 / 否
HY-173433 JV8 Degrader / 否
HY-173561 MS115 Inhibitor / 否
HY-174445 C199 / 否
HY-174453 PROTAC ERα Degrader-12 / 否
HY-174469 PROTAC PI3K/110β degrader-2 / 否
HY-174858 dASK1-VHL / 否
HY-174860 ASK1 ligand 1 Degrader / 否
HY-174861 (S,R,S)-AHPC-CO-C2-PEG-NHCO-C2-COOH / 否
HY-174873 AF151 / 否
HY-174920 PROTAC BRD4 Degrader-34 Inhibitor / 否
HY-176239 PROTAC PI3Kδ degrader-1 / 否
HY-176261 DDD2 Degrader / 否
HY-176489 PROTAC pan-KRAS degrader-1 / 否
HY-176492 E3 Ligase Ligand-linker Conjugate 193 Chemical / 否
HY-176528 PROTAC ERK5 degrader-1 Inhibitor / 否
HY-176530 (S,R,S)-AHPC-Me-amide-C4-Br / 否
HY-400685 SMD-3040 intermediate-2 95.82% 否
HY-44630 VH 032 amide-alkylC6-acid / 否
HY-49515 SOS1 Ligand intermediate-2 Inhibitor / 否
HY-B2171 Carubicin Inducer / 否
HY-D2413 BODIPY FL VH032 / 否
HY-P5915 FAM-DEALA-Hyp-YIPMDDDFQLRSF-NH2 Agonist / 否
HY-RS15648 VHL Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-W245311 E3 ligase Ligand 51 Ligand / 否
HY-W584525 VH032-NH-CO-CH2-NHBoc / 否
HY-W584527 VH032 analogue-1 / 否
HY-W584528 VH032 analogue-2 / 否
HY-W584529 VH032-C2-NH-Boc / 否
HY-W584530 VH032-C4-NH-Boc / 否
HY-W584531 VH032-C6-NH-Boc / 否
HY-W584532 VH032-O-C2-NH-Boc / 否
HY-W584533 VH032-PEG2-NH-BOC / 否
HY-W584534 VH032-CH2-Boc / 否
HY-W584535 VH032-C3-Boc / 否
HY-130845 AR antagonist 1 / 否
HY-136186A (S,R,S)-AHPC-C7-amine dihydrochloride / 否
HY-139334 VH 101 phenol-alkylC6-amine dihydrochloride / 否
HY-139341 Pomalidomide 4'-alkylC3-azide / 否
HY-139343 Pomalidomide 4'-alkylC2-azide / 否
HY-164043 (S,R,S)-AHPC(Me)-amido-C2-acid / 否
HY-168229 PROTAC SMARCA2 degrader-27 Inhibitor / 否
HY-168288 MEK ligand-2 Inhibitor / 否
HY-168290 (S,R,S)-AHPC-Me-12-((4-Bromobutyl)amino)dodecanamide / 否
HY-174856 PROTAC HBeAg degrader-1 Degrader / 否
HY-403544 CbzNH-(C5-O)2-C4-Boc / 否
HY-48682 AKT ligand-2 / 否
HY-49514 SOS1 Ligand intermediate-1 Inhibitor / 否
HY-RS16509 Vhl Mouse Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS22941 Vhl Rat Pre-designed siRNA Set A Pre-designed Sets / 否
HY-W800760 (S,R,S)-AHPC-PEG6-Tos / 否
HY-W937057 (S,R,S)-AHPC-Me-10-bromodecanoic acid / 否
HY-110402 (S,R,S)-AHPC TFA / 否
HY-111905A BRD7-IN-1 free base Inhibitor / 否
HY-111824 VH032-thiol-C6-NH2 / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Vhl NCBI NCBI:7428
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z